Celldex Therapeutics

Historical price data

Celldex Therapeutics is a disciplined, R&D-focused biotech with a 40-year legacy, strategically pivoted to become a leader in developing targeted antibody therapeutics for immunology and oncology. Its most advanced asset, barzolvolimab, a mast cell-depleting KIT inhibitor, has demonstrated compelling late-stage data in chronic urticaria and is advancing in multiple inflammatory indications, positioning the company for near-term commercialization. Celldex's strategy leverages proprietary antibody platforms and in-house capabilities to build a diversified pipeline aimed at addressing root causes of disease beyond symptomatic management.

Proprietary platforms for generating optimized monoclonal and next-generation bispecific antibodies, with integrated in-house capabilities from discovery through GMP manufacturing.

In urticaria, barzolvolimab competes with omalizumab and late-stage BTK inhibitors, differentiating via direct mast cell depletion. In dermatology, it enters crowded markets (AD, PN) dominated by IL-targeting biologics, where its novel mechanism must prove superior efficacy to gain share.